Efficacy and Tolerability of Controlled-Release Paroxetine in the Treatment of Panic Disorder

Sheehan, David V.; Burnham, Daniel B.; Iyengar, Malini; Perera, Philip

doi:10.4088/jcp.v66n0105

Cited by 71 publications

(32 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The present investigation confirms earlier studies, which have demonstrated the efficacy of clonazepam (11,12,21,(28)(29)(30) and paroxetine (18,19,31,32) in separate trials in the treatment of panic disorder. The present study compares clonazepam with paroxetine using a parallel methodology with the same team of health providers.…”

Section: Discussionsupporting

confidence: 81%

“…SSRIs have been prescribed for panic disorder with or without agoraphobia for over a decade and are recommended as first-line treatment for panic disorder on the basis of their favorable safety profile (16). The efficacy and safety profile of the SSRI paroxetine has been demonstrated in the treatment of panic disorder in a number of randomized controlled trials (17)(18)(19). However, the benzodiazepines remain one of the most commonly prescribed therapeutic options for panic disorder (20).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Psychopharmacotherapy of panic disorder: 8-week randomized trial with clonazepam and paroxetine

Nardi¹,

Valença²,

Freire³

et al. 2011

Braz J Med Biol Res

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 81%

Section: Introductionmentioning

confidence: 99%

Psychopharmacotherapy of panic disorder: 8-week randomized trial with clonazepam and paroxetine

Nardi¹,

Valença²,

Freire³

et al. 2011

Braz J Med Biol Res

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 80%

Section: Introductionmentioning

confidence: 99%

Psychopharmacotherapy of panic disorder: 8-week randomized trial with clonazepam and paroxetine

Nardi¹,

Valença²,

Freire³

et al. 2011

Braz J Med Biol Res

View full text Add to dashboard Cite

“…In a 52-week long-term study, it was as effective as the RIMA moclobemide (Tiller et al 1999) (A). Á Paroxetine showed efficacy in DBPC (Ballenger et al 1998;Oehrberg et al 1995;Pollack and Doyle 2003;Sheehan et al 2005) and comparator-controlled studies (Bakker et al 1999;Oehrberg et al 1995;Pollack et al 2007b;Wedekind et al submitted). In a relapse prevention trial over 36 weeks, it was as effective as the TCA clomipramine (Lecrubier and Judge 1997) (A).…”

Section: Panic Disorder and Agoraphobiamentioning

confidence: 99%

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

Bandelow

Zohar

Hollander

et al. 2008

The World Journal of Biological Psychiatry

712

410

View full text Add to dashboard Cite

In this report, which is an update of a guideline published in 2002 (Bandelow et al. 2002, recommendations for the pharmacological treatment of anxiety disorder, obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD) are presented. Since the publication of the first version of this guideline, a substantial number of new randomized controlled studies of anxiolytics have been published. In particular, more relapse prevention studies are now available that show sustained efficacy of anxiolytic drugs. The recommendations, developed by the World Federation of Societies of Biological Psychiatry (WFSBP) Task Force for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders, a consensus panel of 30 international experts, are now based on 510 published randomized, placebo-or comparator-controlled clinical studies (RCTs) and 130 open studies and case reports. First-line treatments for these disorders are selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs) and the calcium channel modulator pregabalin. Tricyclic antidepressants (TCAs) are equally effective for some disorders, but many are less well tolerated than the SSRIs/ SNRIs. In treatment-resistant cases, benzodiazepines may be used when the patient does not have a history of substance abuse disorders. Potential treatment options for patients unresponsive to standard treatments are described in this overview. Although these guidelines focus on medications, non-pharmacological were also considered. Cognitive behavioural therapy (CBT) and other variants of behaviour therapy have been sufficiently investigated in controlled studies in patients with anxiety disorders, OCD, and PTSD to support them being recommended either alone or in combination with the above medicines.

show abstract

Efficacy and Tolerability of Controlled-Release Paroxetine in the Treatment of Panic Disorder

Cited by 71 publications

References 15 publications

Psychopharmacotherapy of panic disorder: 8-week randomized trial with clonazepam and paroxetine

Psychopharmacotherapy of panic disorder: 8-week randomized trial with clonazepam and paroxetine

Psychopharmacotherapy of panic disorder: 8-week randomized trial with clonazepam and paroxetine

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

Contact Info

Product

Resources

About